The electrocardiogram (ECG) is a generally used scientific software that displays cardiac excitability and illness. Many parameters are will be measured and with the development of methodology can now be quantified in an automatic trend, with accuracy and at scale.
Furthermore, these measurements will be heritable and thus genome vast affiliation research inform the underpinning organic mechanisms. In this assessment we describe how we’ve used the sources in UK Biobank to undertake such work. In specific, we deal with a substudy uniquely describing the response to train carried out at scale with accompanying genetic info.
A Body Shape Index (ABSI), hip index, and risk of most cancers in the UK Biobank cohort
Abdominal dimension is related positively with the risk of some cancers however the affect of physique mass index (BMI) and gluteofemoral dimension is unclear as a result of waist and hip circumference are strongly correlated with BMI. We examined associations of 33 cancers with A Body Shape Index (ABSI) and hip index (HI), that are impartial of BMI by design, and in contrast these with waist and hip circumference, utilizing multivariable Cox proportional hazards fashions in UK Biobank.
During a imply follow-up of seven years, 14,682 incident cancers had been ascertained in 200,289 males and 12,965 cancers in 230,326 ladies. In males, ABSI was related positively with cancers of the top and neck (hazard ratio HR = 1.14; 95% confidence interval 1.03-1.26 per one customary deviation increment), esophagus (adenocarcinoma, HR = 1.27; 1.12-1.44), gastric cardia (HR = 1.31; 1.07-1.61), colon (HR = 1.18; 1.10-1.26), rectum (HR = 1.13; 1.04-1.22), lung (adenocarcinoma, HR = 1.16; 1.03-1.30; squamous cell carcinoma [SCC], HR = 1.33; 1.17-1.52), and bladder (HR = 1.15; 1.04-1.27), whereas HI was related inversely with cancers of the esophagus (adenocarcinoma, HR = 0.89; 0.79-1.00), gastric cardia (HR = 0.79; 0.65-0.96), colon (HR = 0.92; 0.86-0.98), liver (HR = 0.86; 0.75-0.98), and a number of myeloma (HR = 0.86; 0.75-1.00).
In ladies, ABSI was related positively with cancers of the top and neck (HR = 1.27; 1.10-1.48), esophagus (SCC, HR = 1.37; 1.07-1.76), colon (HR = 1.08; 1.01-1.16), lung (adenocarcinoma, HR = 1.17; 1.06-1.29; SCC, HR = 1.40; 1.20-1.63; small cell, HR = 1.39; 1.14-1.69), kidney (clear-cell, HR = 1.25; 1.03-1.50), and post-menopausal endometrium (HR = 1.11; 1.02-1.20), whereas HI was related inversely with pores and skin SCC (HR = 0.91; 0.83-0.99), post-menopausal kidney most cancers (HR = 0.77; 0.67-0.88), and post-menopausal melanoma (HR = 0.90; 0.83-0.98).
Unusually, ABSI was related inversely with melanoma in males (HR = 0.89; 0.82-0.96) and pre-menopausal ladies (HR = 0.77; 0.65-0.91). Waist and hip circumference mirrored associations with BMI, when examined individually, and supplied biased risk estimates, when mixed with BMI. In conclusion, preferential optimistic associations of ABSI or inverse of HI with a number of main cancers point out an necessary function of things figuring out physique form in most cancers improvement.
Brain imaging earlier than and after COVID-19 in UK Biobank
There is powerful proof for brain-related pathologies in COVID-19, a few of which may very well be a consequence of viral neurotropism. The overwhelming majority of mind imaging research up to now have targeted on qualitative, gross pathology of reasonable to extreme circumstances, typically carried out on hospitalised sufferers. It stays unknown nevertheless whether or not the influence of COVID-19 will be detected in milder circumstances, in a quantitative and automated method, and whether or not this could reveal a doable mechanism for the unfold of the illness.

UK Biobank scanned over 40,000 individuals earlier than the beginning of the COVID-19 pandemic, making it doable to ask again in 2021 tons of of previously-imaged individuals for a second imaging go to. Here, we studied the results of the illness in the mind utilizing multimodal knowledge from 782 individuals from the UK Biobank COVID-19 re-imaging research, with 394 individuals having examined optimistic for SARS-CoV-2 an infection between their two scans. We used structural and practical mind scans from earlier than and after an infection, to match longitudinal mind adjustments between these 394 COVID-19 sufferers and 388 controls who had been matched for age, intercourse, ethnicity and interval between scans.
We recognized important results of COVID-19 in the mind with a lack of gray matter in the left parahippocampal gyrus, the left lateral orbitofrontal cortex and the left insula. When trying over your entire cortical floor, these outcomes prolonged to the anterior cingulate cortex, supramarginal gyrus and temporal pole. We additional in contrast COVID-19 sufferers who had been hospitalised (n=15) with those that had not (n=379), and whereas outcomes weren’t important, we discovered comparatively related findings to the COVID-19 vs management group comparability, with, in addition, a better lack of gray matter in the cingulate cortex, central nucleus of the amygdala and hippocampal cornu ammonis (all |Z|>3). Our findings thus constantly relate to lack of gray matter in limbic cortical areas immediately linked to the first olfactory and gustatory system.
Unlike in submit hoc illness research, the provision of pre-infection imaging knowledge helps keep away from the hazard of pre-existing risk components or scientific situations being mis-interpreted as illness results. Since a doable entry level of the virus to the central nervous system is likely to be through the olfactory mucosa and the olfactory bulb, these mind imaging outcomes is likely to be the in vivo hallmark of the unfold of the illness (or the virus itself) through olfactory and gustatory pathways.
BBMRI-ERIC Negotiator: Implementing Efficient Access to Biobanks
Various organic sources, similar to biobanks and disease-specific registries, have develop into indispensable sources to raised perceive the epidemiology and organic mechanisms of illness and are basic for advancing medical analysis. Nevertheless, biobanks and related sources nonetheless face important challenges to develop into extra findable and accessible by customers on each nationwide and world scales.
One of the primary challenges for customers is to seek out related sources utilizing cataloging and search providers such because the BBMRI-ERIC Directory, operated by European Research Infrastructure on Biobanking and Biomolecular Resources (BBMRI-ERIC), as these typically don’t include the knowledge wanted by the researchers to resolve if the useful resource has related materials/knowledge; these sources are solely weakly characterised. Hence, the researcher is usually left with too many sources to discover and examine. In addition, sources typically have advanced procedures for accessing holdings, notably for depletable organic supplies.
This article focuses on designing a system for efficient negotiation of entry to holdings, in which a researcher can strategy many sources concurrently, whereas giving every useful resource workforce the flexibility to implement their very own mechanisms to test if the fabric/knowledge can be found and to resolve if entry needs to be supplied. The BBMRI-ERIC has developed and carried out an entry and negotiation software known as the BBMRI-ERIC Negotiator.
PRDM16 Polyclonal Antibody |
|||
A-2016 | EpiGentek |
|
|
PRDM17 Polyclonal Antibody |
|||
A-2017 | EpiGentek |
|
|
EZH1 Polyclonal Antibody |
|||
A-2018 | EpiGentek |
|
|
HSF1 Polyclonal Antibody |
|||
A-2401 | EpiGentek |
|
|
PRMT3 Polyclonal Antibody |
|||
A-3003 | EpiGentek |
|
|
SET1 Polyclonal Antibody |
|||
A-3011 | EpiGentek |
|
|
SET07 Polyclonal Antibody |
|||
A-3013 | EpiGentek |
|
|
LSD1 Polyclonal Antibody |
|||
A-3018 | EpiGentek |
|
|
HDAC10 Polyclonal Antibody |
|||
A-4010 | EpiGentek |
|
|
PCAF Polyclonal Antibody |
|||
A-4012 | EpiGentek |
|
|
Histone H3K9ac (Acetyl H3K9) Polyclonal Antibody |
|||
A-4022 | EpiGentek |
|
|
Histone H3K14ac (Acetyl H3K14) Polyclonal Antibody |
|||
A-4023 | EpiGentek |
|
|
Histone H3K18ac (Acetyl H3K18) Polyclonal Antibody |
|||
A-4024 | EpiGentek |
|
|
Histone H3K23ac (Acetyl H3K23) Polyclonal Antibody |
|||
A-4025 | EpiGentek |
|
|
Histone H3K56ac (Acetyl H3K56) Polyclonal Antibody |
|||
A-4026 | EpiGentek |
|
|
Histone H3K4me1 (H3K4 Monomethyl) Polyclonal Antibody |
|||
A-4031 | EpiGentek |
|
|
Histone H3K4me2 (H3K4 Dimethyl) Polyclonal Antibody |
|||
A-4032 | EpiGentek |
|
|
Histone H3K4me3 (H3K4 Trimethyl) Polyclonal Antibody |
|||
A-4033 | EpiGentek |
|
|
Histone H3K9me1 (H3K9 Monomethyl) Polyclonal Antibody |
|||
A-4034 | EpiGentek |
|
|
Histone H3K9me2 (H3K9 Dimethyl) Polyclonal Antibody |
|||
A-4035 | EpiGentek |
|
|
Histone H3K9me3 (H3K9 Trimethyl) Polyclonal Antibody |
|||
A-4036 | EpiGentek |
|
|
Histone H3K27me1 (H3K27 Monomethyl) Polyclonal Antibody |
|||
A-4037 | EpiGentek |
|
|
Histone H3K27me2 (H3K27 Dimethyl) Polyclonal Antibody |
|||
A-4038 | EpiGentek |
|
|
Histone H3K27me3 (H3K27 Trimethyl) Polyclonal Antibody |
|||
A-4039 | EpiGentek |
|
|
Histone H3K36me1 (H3K36 Monomethyl) Polyclonal Antibody |
|||
A-4040 | EpiGentek |
|
|
Histone H3K36me2 (H3K36 Dimethyl) Polyclonal Antibody |
|||
A-4041 | EpiGentek |
|
|
Histone H3K36me3 (H3K36 Trimethyl) Polyclonal Antibody |
|||
A-4042 | EpiGentek |
|
|
Histone H3K79me1 (H3K79 Monomethyl) Polyclonal Antibody |
|||
A-4043 | EpiGentek |
|
|
Histone H3K79me2 (H3K79 Dimethyl) Polyclonal Antibody |
|||
A-4044 | EpiGentek |
|
|
Histone H3K79me3 (H3K79 Trimethyl) Polyclonal Antibody |
|||
A-4045 | EpiGentek |
|
|
Histone H4K20me1 (H4K20 Monomethyl) Polyclonal Antibody |
|||
A-4046 | EpiGentek |
|
|
Histone H4K20me2 (H4K20 Dimethyl) Polyclonal Antibody |
|||
A-4047 | EpiGentek |
|
|
Histone H4K20me3 (H4K20 Trimethyl) Polyclonal Antibody |
|||
A-4048 | EpiGentek |
|
|
Histone H3K27ac (Acetyl H3K27) Polyclonal Antibody |
|||
A-4708 | EpiGentek |
|
|
CRISPR Cas9 Monoclonal Antibody [7A9] |
|||
A-9000 | EpiGentek |
|
|
CRISPR/Cas9 (SaCas9) Monoclonal Antibody [6H4] |
|||
A-9001 | EpiGentek |
|
|
CLIMP-63 Polyclonal Antibody |
|||
A-0701 | EpiGentek |
|
|
DNMT3A Polyclonal Antibody |
|||
A-1003 | EpiGentek |
|
|
DNMT3B Polyclonal Antibody |
|||
A-1004 | EpiGentek |
|
|
DNMT3L Polyclonal Antibody |
|||
A-1005 | EpiGentek |
|
|
MBD3 Polyclonal Antibody |
|||
A-1008 | EpiGentek |
|
|
MGMT Polyclonal Antibody |
|||
A-1010 | EpiGentek |
|
|
MeCP2 Polyclonal Antibody |
|||
A-1012 | EpiGentek |
|
|
TET1 Polyclonal Antibody |
|||
A-1020 | EpiGentek |
|
|
DNMT1 Polyclonal Antibody |
|||
A-1700 | EpiGentek |
|
|
TET2 Polyclonal Antibody |
|||
A-1701 | EpiGentek |
|
|
MBD2 Polyclonal Antibody |
|||
A-1713 | EpiGentek |
|
|
PRDM2 Polyclonal Antibody |
|||
A-2002 | EpiGentek |
|
|
PRDM3 Polyclonal Antibody |
|||
A-2003 | EpiGentek |
|
|
PRDM6 Polyclonal Antibody |
|||
A-2006 | EpiGentek |
|
|
PRDM12 Polyclonal Antibody |
|||
A-2012 | EpiGentek |
|
|
PRDM14 Polyclonal Antibody |
|||
A-2014 | EpiGentek |
|
|
EZH2 Polyclonal Antibody |
|||
A-2019 | EpiGentek |
|
|
EED Polyclonal Antibody |
|||
A-2020 | EpiGentek |
|
|
Swi2/SNF2 Polyclonal Antibody |
|||
A-2023 | EpiGentek |
|
|
SNFa/BRM Polyclonal Antibody |
|||
A-2025 | EpiGentek |
|
|
Ini1 Polyclonal Antibody |
|||
A-2026 | EpiGentek |
|
|
RNA Polymerase II Monoclonal Antibody [CTD4H8] |
|||
A-2032 | EpiGentek |
|
|
CBX5 Polyclonal Antibody |
|||
A-2701 | EpiGentek |
|
|
EGLN1 Polyclonal Antibody |
|||
A-2702 | EpiGentek |
|
|
RBBP4 Polyclonal Antibody |
|||
A-2703 | EpiGentek |
|
|
SIN3A Polyclonal Antibody |
|||
A-2704 | EpiGentek |
|
|
CTBP1 Polyclonal Antibody |
|||
A-2705 | EpiGentek |
|
|
PADI4 Polyclonal Antibody |
|||
A-2706 | EpiGentek |
|
|
SMARCA5 Polyclonal Antibody |
|||
A-2707 | EpiGentek |
|
|
IDH1 Polyclonal Antibody |
|||
A-2708 | EpiGentek |
|
|
CHD4 Polyclonal Antibody |
|||
A-2709 | EpiGentek |
|
|
CHAF1A Polyclonal Antibody |
|||
A-2710 | EpiGentek |
|
|
BRD7 Polyclonal Antibody |
|||
A-2712 | EpiGentek |
|
|
UHRF1 Polyclonal Antibody |
|||
A-2714 | EpiGentek |
|
|
UHRF2 Polyclonal Antibody |
|||
A-2715 | EpiGentek |
|
|
SMARCE1 Polyclonal Antibody |
|||
A-2716 | EpiGentek |
|
|
ACTL6A Polyclonal Antibody |
|||
A-2717 | EpiGentek |
|
|
MPG Polyclonal Antibody |
|||
A-2718 | EpiGentek |
|
|
HIF1AN Polyclonal Antibody |
|||
A-2719 | EpiGentek |
|
|
RNF2 Polyclonal Antibody |
|||
A-2720 | EpiGentek |
|
|
PCGF6 Polyclonal Antibody |
|||
A-2721 | EpiGentek |
|
|
SMARCB1 Polyclonal Antibody |
|||
A-2722 | EpiGentek |
|
|
ALKBH3 Polyclonal Antibody |
|||
A-2723 | EpiGentek |
|
|
BBOX1 Polyclonal Antibody |
|||
A-2724 | EpiGentek |
|
|
BTAF1 Polyclonal Antibody |
|||
A-2725 | EpiGentek |
|
|
CXXC1 Polyclonal Antibody |
|||
A-2726 | EpiGentek |
|
|
KDM4B Polyclonal Antibody |
|||
A-2727 | EpiGentek |
|
|
HELLS Polyclonal Antibody |
|||
A-2728 | EpiGentek |
|
|
ING3 Polyclonal Antibody |
|||
A-2729 | EpiGentek |
|
|
ING4 Polyclonal Antibody |
|||
A-2730 | EpiGentek |
|
|
PHC1 Polyclonal Antibody |
|||
A-2731 | EpiGentek |
|
|
SMARCAD1 Polyclonal Antibody |
|||
A-2732 | EpiGentek |
|
|
USP16 Polyclonal Antibody |
|||
A-2733 | EpiGentek |
|
|
SMARCC1 Polyclonal Antibody |
|||
A-2734 | EpiGentek |
|
|
ERCC6L Polyclonal Antibody |
|||
A-2735 | EpiGentek |
|
|
SMYD5 Polyclonal Antibody |
|||
A-2736 | EpiGentek |
|
|
ATF2 Polyclonal Antibody |
|||
A-2738 | EpiGentek |
|
|
BMI1 Polyclonal Antibody |
|||
A-2739 | EpiGentek |
|
|
CTBP2 Polyclonal Antibody |
|||
A-2740 | EpiGentek |
|
|
CTCF Polyclonal Antibody |
|||
A-2741 | EpiGentek |
|
|
MTA2 Polyclonal Antibody |
|||
A-2742 | EpiGentek |
|
|
PMS1 Polyclonal Antibody |
|||
A-2744 | EpiGentek |
|
|
SFN Polyclonal Antibody |
|||
A-2745 | EpiGentek |
|
|
SMARCA4 Polyclonal Antibody |
|||
A-2746 | EpiGentek |
|
|
SMARCAL1 Polyclonal Antibody |
|||
A-2747 | EpiGentek |
|
|
SMARCC2 Polyclonal Antibody |
|||
A-2748 | EpiGentek |
|
|
MuERVL-Gag Polyclonal Antibody |
|||
A-2801 | EpiGentek |
|
|
PRMT1 Polyclonal Antibody |
|||
A-3001 | EpiGentek |
|
|
PRMT2 Polyclonal Antibody |
|||
A-3002 | EpiGentek |
|
|
PRMT4 Polyclonal Antibody |
|||
A-3004 | EpiGentek |
|
|
PRMT5 Polyclonal Antibody |
|||
A-3005 | EpiGentek |
|
|
PRMT7 Polyclonal Antibody |
|||
A-3007 | EpiGentek |
|
|
SUV39H2 Polyclonal Antibody |
|||
A-3010 | EpiGentek |
|
|
SET9 Polyclonal Antibody |
|||
A-3014 | EpiGentek |
|
|
CBX4 Polyclonal Antibody |
|||
A-3016 | EpiGentek |
|
|
CBX8 Polyclonal Antibody |
|||
A-3017 | EpiGentek |
|
|
EHMT2 Polyclonal Antibody |
|||
A-3019 | EpiGentek |
|
|
SETDB1 Polyclonal Antibody |
|||
A-3700 | EpiGentek |
|
|
KAT5 Polyclonal Antibody |
|||
A-3701 | EpiGentek |
|
|
SETD1B Polyclonal Antibody |
|||
A-3702 | EpiGentek |
|
|
KDM3B Polyclonal Antibody |
|||
A-3703 | EpiGentek |
|
|
KDM3A Polyclonal Antibody |
|||
A-3704 | EpiGentek |
|
|
Histone H3R2 Dimethyl Symmetric (H3R2me2s) Polyclonal Antibody |
|||
A-3705 | EpiGentek |
|
|
Histone H3R8 Dimethyl Symmetric (H3R8me2s) Polyclonal Antibody |
|||
A-3706 | EpiGentek |
|
|
Histone H3R26 Dimethyl Asymmetric (H3R26me2a) Polyclonal Antibody |
|||
A-3707 | EpiGentek |
|
|
Histone H4R3 Dimethyl Asymmetric (H4R3me2a) Polyclonal Antibody |
|||
A-3708 | EpiGentek |
|
|
Histone H3R17 Dimethyl Asymmetric (H3R17me2a) Polyclonal Antibody |
|||
A-3709 | EpiGentek |
|
|
Histone H3R17 Monomethyl (H3R17me1) Polyclonal Antibody |
|||
A-3710 | EpiGentek |
|
|
Histone H3R17 Dimethyl Symmetric (H3R17me2s) Polyclonal Antibody |
|||
A-3711 | EpiGentek |
|
|
Histone H3R26 Dimethyl Symmetric (H3R26me2s) Polyclonal Antibody |
|||
A-3712 | EpiGentek |
|
|
Histone H3R2 Monomethyl (H3R2me1) Polyclonal Antibody |
|||
A-3713 | EpiGentek |
|
|
Histone H3R2 Dimethyl Asymmetric (H3R2me2a) Polyclonal Antibody |
|||
A-3714 | EpiGentek |
|
|
Histone H3R8 Monomethyl (H3R8me1) Polyclonal Antibody |
|||
A-3715 | EpiGentek |
|
|
Histone H3R8 Dimethyl Asymmetric (H3R8me2a) Polyclonal Antibody |
|||
A-3716 | EpiGentek |
|
|
Histone H4R3 Monomethyl (H4R3me1) Polyclonal Antibody |
|||
A-3717 | EpiGentek |
|
|
Histone H4R3 Dimethyl Symmetric (H4R3me2s) Polyclonal Antibody |
|||
A-3718 | EpiGentek |
|
|
Histone H3R26 Monomethyl (H3R26me1) Polyclonal Antibody |
|||
A-3719 | EpiGentek |
|
|
SETD2 Polyclonal Antibody |
|||
A-3720 | EpiGentek |
|
|
Histone H3K14me1 (H3K14 Monomethyl) Polyclonal Antibody |
|||
A-3721 | EpiGentek |
|
|
Histone H3K14me2 (H3K14 Dimethyl) Polyclonal Antibody |
|||
A-3722 | EpiGentek |
|
|
Histone H3K14me3 (H3K14 Trimethyl) Polyclonal Antibody |
|||
A-3723 | EpiGentek |
|
|
JMJD6 Polyclonal Antibody |
|||
A-3724 | EpiGentek |
|
|
Pan Kme2 (Dimethyl Lysine) Polyclonal Antibody |
|||
A-3725 | EpiGentek |
|
|
MLL5 Polyclonal Antibody |
|||
A-3726 | EpiGentek |
|
|
ASH2L Polyclonal Antibody |
|||
A-3727 | EpiGentek |
|
|
KDM1A Polyclonal Antibody |
|||
A-3728 | EpiGentek |
|
|
MBD5 Polyclonal Antibody |
|||
A-3729 | EpiGentek |
|
|
HDAC3 Monoclonal Antibody [A10B1] |
|||
A-4003 | EpiGentek |
|
|
HDAC4 Polyclonal Antibody |
|||
A-4004 | EpiGentek |
|
|
HDAC5 Polyclonal Antibody |
|||
A-4005 | EpiGentek |
|
|
HDAC6 Polyclonal Antibody |
|||
A-4006 | EpiGentek |
|
|
HDAC7 Polyclonal Antibody |
|||
A-4007 | EpiGentek |
|
|
HDAC11 Polyclonal Antibody |
|||
A-4011 | EpiGentek |
|
|
GCN5 Polyclonal Antibody |
|||
A-4013 | EpiGentek |
|
|
HAT1 Polyclonal Antibody |
|||
A-4014 | EpiGentek |
|
|
HP1-alpha Polyclonal Antibody |
|||
A-4015 | EpiGentek |
|
|
HP1-beta Polyclonal Antibody |
|||
A-4016 | EpiGentek |
|
|
HP1-gamma Polyclonal Antibody |
|||
A-4017 | EpiGentek |
|
|
SAP18 Polyclonal Antibody |
|||
A-4018 | EpiGentek |
|
|
SAP30 Polyclonal Antibody |
|||
A-4019 | EpiGentek |
|
|
p300 Polyclonal Antibody |
|||
A-4020 | EpiGentek |
|
|
Histone H3K9/14ac (Acetyl H3K9/14) Polyclonal Antibody |
|||
A-4021 | EpiGentek |
|
|
Histone H4K5ac (Acetyl H4K5) Polyclonal Antibody |
|||
A-4027 | EpiGentek |
|
|
Histone H4K8ac (Acetyl H4K8) Polyclonal Antibody |
|||
A-4028 | EpiGentek |
|
|
Histone H4K12ac (Acetyl H4K12) Polyclonal Antibody |
|||
A-4029 | EpiGentek |
|
|
Phospho-Histone H3 (Ser28) Polyclonal Antibody |
|||
A-4050 | EpiGentek |
|
|
Histone H2AK5ac (Acetyl H2AK5) Polyclonal Antibody |
|||
A-4300 | EpiGentek |
|
|
SIRT1 Polyclonal Antibody |
|||
A-4700 | EpiGentek |
|
|
SIRT7 Polyclonal Antibody |
|||
A-4701 | EpiGentek |
|
|
SIRT2 Polyclonal Antibody |
|||
A-4702 | EpiGentek |
|
|
The Negotiator allows entry negotiation to greater than 600 biobanks from the BBMRI-ERIC Directory and different discovery providers similar to GBA/BBMRI-ERIC Locator or RD-Connect Finder. This article summarizes the rules that guided the design of the software, the terminology used and underlying knowledge mannequin, request workflows, authentication and authorization mechanism(s), and the mechanisms and monitoring processes to stimulate the specified habits of the sources: to successfully ship entry to organic materials and knowledge.